Two enterprises under China National Pharmaceutical Group Co Ltd (Sinopharm) signed a strategic cooperation agreement respectively with Fresenius Kabi (China) Co Ltd on March 12, marking a new chapter of stronger multilateral collaboration.

Participants of the signing ceremony pose for a group photo. [Photo/sinopharm.com]

Liu Jingzhen, chairman of Sinopharm, speaks at the signing ceremony. [Photo/sinopharm.com]

The agreements signed among Sinopharm Group Co Ltd (Sinopharm Holding), China Sinopharm International Corporation (Sinopharm International) and Fresenius Kabi (China) Co Ltd aim to further consolidate and expand cooperation in such areas as pharmaceutical sales, warehousing, distribution, healthcare, medical care and wellness, with the goal of bringing better products and services to the Chinese people, said Liu Jingzhen, chairman of Sinopharm.

In the future, Sinopharm and Fresenius Kabi will continue to support each other, contributing to the development of China's medical and health industry, the well-being of people around the world, and the building of a global community of health for all, Liu added.

Pierluigi Antonelli, president of Fresenius Kabi, speaks at the signing ceremony. [Photo/sinopharm.com]

Pierluigi Antonelli, president of Fresenius Kabi, said that Fresenius Kabi has always attached great importance to the Chinese market and its cooperation with Sinopharm. After more than 40 years of collaboration, a profound friendship and high-level mutual trust have been established. Building upon this foundation, through the signing of the strategic cooperation agreements, both sides will continue to work together, leverage their respective strengths and jointly create a new ecology in the health sector.

Sinopharm Holding and Fresenius Kabi (China) Co Ltd sign a strategic cooperation agreement on March 12. [Photo/sinopharm.com]

Sinopharm International and Fresenius Kabi (China) Co Ltd sign a strategic cooperation agreement on March 12. [Photo/sinopharm.com]

Representing their companies, Chen Zhanyu, vice-chairman of Sinopharm Holding, Yang Weiping, president of Fresenius Kabi SSPC, Zhou Song, chairman of Sinopharm International, and Ulf Jansson, executive vice-president region Asia Pacific of Fresenius Kabi, signed the agreements.

Since 1982, Sinopharm and Fresenius Kabi have been working together. Faced with challenges and opportunities in the pharmaceutical industry, both parties will continue win-win cooperation, constantly explore new areas of collaboration and jointly create a new chapter in the health sector.

Also present at the event were Jin Bin, deputy general manager of Sinopharm, Shi Shengyi, vice-president of Fresenius Kabi SSPC, Liang Hongjun, chairman of China National Pharmaceutical Investment Co Ltd and director of Fresenius Kabi SSPC, along with Andreas Duenkel, chief financial officer, Marc-Alexander Mahl, president of pharma & nutrition, and Matthias Tyssen, head of corporate development and executive vice-president of Fresenius Kabi.